GB201417707D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB201417707D0
GB201417707D0 GBGB1417707.5A GB201417707A GB201417707D0 GB 201417707 D0 GB201417707 D0 GB 201417707D0 GB 201417707 A GB201417707 A GB 201417707A GB 201417707 D0 GB201417707 D0 GB 201417707D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1417707.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VIRAL Ltd
Original Assignee
VIRAL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51946966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201417707(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by VIRAL Ltd filed Critical VIRAL Ltd
Priority to GBGB1417707.5A priority Critical patent/GB201417707D0/en
Publication of GB201417707D0 publication Critical patent/GB201417707D0/en
Priority to NZ731323A priority patent/NZ731323A/en
Priority to PE2017000576A priority patent/PE20170949A1/es
Priority to SI201530634T priority patent/SI3204375T1/sl
Priority to TR2019/03362T priority patent/TR201903362T4/tr
Priority to PL15782033T priority patent/PL3204375T3/pl
Priority to SG11201702766YA priority patent/SG11201702766YA/en
Priority to ARP150103215A priority patent/AR102181A1/es
Priority to AU2015329778A priority patent/AU2015329778B2/en
Priority to RS20190515A priority patent/RS58706B1/sr
Priority to HRP20190808TT priority patent/HRP20190808T1/hr
Priority to KR1020177012311A priority patent/KR102561796B1/ko
Priority to PCT/GB2015/052920 priority patent/WO2016055780A1/en
Priority to DK15782033.3T priority patent/DK3204375T3/en
Priority to BR112017007311-0A priority patent/BR112017007311B1/pt
Priority to SM20190249T priority patent/SMT201900249T1/it
Priority to US15/517,290 priority patent/US10106539B2/en
Priority to CN201580066385.4A priority patent/CN107108557B/zh
Priority to ES15782033T priority patent/ES2718976T3/es
Priority to MX2017004425A priority patent/MX373233B/es
Priority to EP15782033.3A priority patent/EP3204375B1/en
Priority to CA2963740A priority patent/CA2963740C/en
Priority to KR1020237025697A priority patent/KR20230116097A/ko
Priority to HUE15782033A priority patent/HUE043553T2/hu
Priority to PT15782033T priority patent/PT3204375T/pt
Priority to RU2017113026A priority patent/RU2734248C2/ru
Priority to LTEP15782033.3T priority patent/LT3204375T/lt
Priority to JP2017519320A priority patent/JP6695334B2/ja
Priority to TW104133092A priority patent/TWI718107B/zh
Priority to CL2017000839A priority patent/CL2017000839A1/es
Priority to CONC2017/0004603A priority patent/CO2017004603A2/es
Priority to CY20191100403T priority patent/CY1121564T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1417707.5A 2014-10-07 2014-10-07 Pharmaceutical compounds Ceased GB201417707D0 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
GBGB1417707.5A GB201417707D0 (en) 2014-10-07 2014-10-07 Pharmaceutical compounds
LTEP15782033.3T LT3204375T (lt) 2014-10-07 2015-10-06 Spiro-indolinai, skirti respiracinio sincitinio viruso (rsv) infekcijos gydymui ir profilaktikai
JP2017519320A JP6695334B2 (ja) 2014-10-07 2015-10-06 呼吸器合胞体ウイルス感染症(rsv)の治療又は予防のためのスピロインドリン
SM20190249T SMT201900249T1 (it) 2014-10-07 2015-10-06 Spiro-indoline per il trattamento e la profilassi di un'infezione da virus respiratorio sinciziale (rsv)
US15/517,290 US10106539B2 (en) 2014-10-07 2015-10-06 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV)
SI201530634T SI3204375T1 (sl) 2014-10-07 2015-10-06 Spiroindolini za zdravljenje in profilakso okužb z respiratornim sincicialnim virusom (rsv)
TR2019/03362T TR201903362T4 (tr) 2014-10-07 2015-10-06 Respiratuvar sinsitiyal virüs enfeksiyonunun (rsv) tedavisi ve profilaksisinde spiro-indolinler.
PL15782033T PL3204375T3 (pl) 2014-10-07 2015-10-06 Spiroindoliny do leczenia i zapobiegania zakażeniu syncytialnym wirusem nabłonka oddechowego (RSV)
SG11201702766YA SG11201702766YA (en) 2014-10-07 2015-10-06 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
ARP150103215A AR102181A1 (es) 2014-10-07 2015-10-06 Derivados de pirrolopiridina y su uso en el tratamiento de una infección por rsv
AU2015329778A AU2015329778B2 (en) 2014-10-07 2015-10-06 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV)
RS20190515A RS58706B1 (sr) 2014-10-07 2015-10-06 Spiro-indolini za lečenje i profilaksu infekcije respiratornim sincicijalnim virusom
HRP20190808TT HRP20190808T1 (hr) 2014-10-07 2015-10-06 Spiro-indolini za liječenje i profilaksu infekcije respiratornim sincicijskim virusom (rsv)
KR1020177012311A KR102561796B1 (ko) 2014-10-07 2015-10-06 호흡기 세포 융합 바이러스 감염의 치료 및 예방을 위한 스피로-인돌린
PCT/GB2015/052920 WO2016055780A1 (en) 2014-10-07 2015-10-06 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
DK15782033.3T DK3204375T3 (en) 2014-10-07 2015-10-06 Spiro indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV)
BR112017007311-0A BR112017007311B1 (pt) 2014-10-07 2015-10-06 Espiro-indols para o tratamento e profilaxia da infecção respiratória do vírus sincicial (rsv)
NZ731323A NZ731323A (en) 2014-10-07 2015-10-06 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
PE2017000576A PE20170949A1 (es) 2014-10-07 2015-10-06 Espiroindolinas para el tratamiento y profilaxis de infeccion por virus respiratorio sincitial (rsv)
CN201580066385.4A CN107108557B (zh) 2014-10-07 2015-10-06 用于治疗和预防呼吸道合胞体病毒(rsv)感染的螺环二氢吲哚类
ES15782033T ES2718976T3 (es) 2014-10-07 2015-10-06 Espiro-indolinas para el tratamiento y la profilaxis de la infección por el virus respiratorio sincitial (VRS)
MX2017004425A MX373233B (es) 2014-10-07 2015-10-06 Indolinas espiro para el tratamiento y profilaxis de infección por virus sincitial respiratorio (rsv).
EP15782033.3A EP3204375B1 (en) 2014-10-07 2015-10-06 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
CA2963740A CA2963740C (en) 2014-10-07 2015-10-06 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
KR1020237025697A KR20230116097A (ko) 2014-10-07 2015-10-06 호흡기 세포 융합 바이러스 감염의 치료 및 예방을위한 스피로-인돌린
HUE15782033A HUE043553T2 (hu) 2014-10-07 2015-10-06 Spiroindolin vegyületek a légúti óriás sejtes vírusfertõzés (RSV) kezeléséhez és megelõzéséhez
PT15782033T PT3204375T (pt) 2014-10-07 2015-10-06 Espiro-indolinas para o tratamento e profilaxia da infeção pelo vírus sincicial respiratório (rsv)
RU2017113026A RU2734248C2 (ru) 2014-10-07 2015-10-06 Спироиндолиновые соединения для лечения и профилактики респираторно-синцитиального вируса (rsv)
TW104133092A TWI718107B (zh) 2014-10-07 2015-10-07 醫藥化合物
CL2017000839A CL2017000839A1 (es) 2014-10-07 2017-04-06 Espiroindolinas para el tratamiento y profilaxis de infección por virus respiratorio sincitial (rsv)
CONC2017/0004603A CO2017004603A2 (es) 2014-10-07 2017-05-05 Inhibidores de replicación del virus respiratorio inicial (rsv) derivados de 1´-[1h- 1,3-benzodiazol-2-il]metil}- espiro[ciclopropano-1,3'-indol]-2'-ona o 1´-[1h-1,3- benzodiazol-2-il]metil)espiro[ciclopropano-1,3'-pirrolo [2,3-c]piridin]'(1'h)-ona, composiciones que los comprenden y métodos de preparación
CY20191100403T CY1121564T1 (el) 2014-10-07 2019-04-11 Σπειρο-ινδολινες για τη θεραπεια και την προφυλαξη απο τη λοιμωξη απο τον αναπνευστικο συγκυτιακο ιο (rsv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417707.5A GB201417707D0 (en) 2014-10-07 2014-10-07 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB201417707D0 true GB201417707D0 (en) 2014-11-19

Family

ID=51946966

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1417707.5A Ceased GB201417707D0 (en) 2014-10-07 2014-10-07 Pharmaceutical compounds

Country Status (31)

Country Link
US (1) US10106539B2 (cg-RX-API-DMAC10.html)
EP (1) EP3204375B1 (cg-RX-API-DMAC10.html)
JP (1) JP6695334B2 (cg-RX-API-DMAC10.html)
KR (2) KR20230116097A (cg-RX-API-DMAC10.html)
CN (1) CN107108557B (cg-RX-API-DMAC10.html)
AR (1) AR102181A1 (cg-RX-API-DMAC10.html)
AU (1) AU2015329778B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017007311B1 (cg-RX-API-DMAC10.html)
CA (1) CA2963740C (cg-RX-API-DMAC10.html)
CL (1) CL2017000839A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017004603A2 (cg-RX-API-DMAC10.html)
CY (1) CY1121564T1 (cg-RX-API-DMAC10.html)
DK (1) DK3204375T3 (cg-RX-API-DMAC10.html)
ES (1) ES2718976T3 (cg-RX-API-DMAC10.html)
GB (1) GB201417707D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20190808T1 (cg-RX-API-DMAC10.html)
HU (1) HUE043553T2 (cg-RX-API-DMAC10.html)
LT (1) LT3204375T (cg-RX-API-DMAC10.html)
MX (1) MX373233B (cg-RX-API-DMAC10.html)
NZ (1) NZ731323A (cg-RX-API-DMAC10.html)
PE (1) PE20170949A1 (cg-RX-API-DMAC10.html)
PL (1) PL3204375T3 (cg-RX-API-DMAC10.html)
PT (1) PT3204375T (cg-RX-API-DMAC10.html)
RS (1) RS58706B1 (cg-RX-API-DMAC10.html)
RU (1) RU2734248C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201702766YA (cg-RX-API-DMAC10.html)
SI (1) SI3204375T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201900249T1 (cg-RX-API-DMAC10.html)
TR (1) TR201903362T4 (cg-RX-API-DMAC10.html)
TW (1) TWI718107B (cg-RX-API-DMAC10.html)
WO (1) WO2016055780A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197908A1 (zh) * 2015-06-08 2016-12-15 南京明德新药研发股份有限公司 咪唑衍生物及其中间体的制备方法和晶型
WO2018025043A1 (en) 2016-08-04 2018-02-08 ReViral Limited Pyrimidine derivatives and their use in treating or preventing a respiratory syncytial virus infection
GB201711704D0 (en) * 2017-07-20 2017-09-06 Reviral Ltd Pharmaceutical compounds
GB201721812D0 (en) * 2017-12-22 2018-02-07 Reviral Ltd Pharmaceutical compounds
CN116077494A (zh) * 2023-01-11 2023-05-09 黑龙江中医药大学 一种治疗呼吸道合胞病毒的药物组合物及其制备方法
WO2024174953A1 (zh) * 2023-02-21 2024-08-29 苏州隆博泰药业有限公司 苯并咪唑类衍生物及其医药用途
WO2024252355A1 (en) 2023-06-08 2024-12-12 Pfizer Inc. Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv
WO2025120500A1 (en) 2023-12-06 2025-06-12 Pfizer Inc. Benzodiazepine compounds as n-protein inhibitors
CN122580320A (zh) 2024-01-16 2026-08-14 辉瑞大药厂 作为n-蛋白抑制剂的苯二氮䓬吡唑甲酰胺类
WO2025248535A1 (en) * 2024-05-29 2025-12-04 Zydus Lifesciences Limited Novel spirocyclic compounds to treat viral infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57102863A (en) * 1980-12-16 1982-06-26 Takeda Chem Ind Ltd Spiroindolinone and its preparation
RU2184735C2 (ru) * 1998-01-23 2002-07-10 Санкио Компани, Лимитед Производные спиропиперидина, лекарственное средство, способ профилактики или лечения
EP1418175A1 (en) * 1999-06-28 2004-05-12 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
US6919331B2 (en) 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
US7205328B2 (en) * 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
EP1802637B1 (en) 2004-10-13 2008-10-15 Merck & Co., Inc. Cgrp receptor antagonists
US20100278835A1 (en) 2009-03-10 2010-11-04 Astrazeneca Uk Limited Novel compounds 660
GB201119538D0 (en) * 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
AU2013334001B2 (en) 2012-10-16 2017-07-20 Janssen Sciences Ireland Uc RSV antiviral compounds
KR20160007629A (ko) * 2013-05-14 2016-01-20 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 아자-옥소-인돌
JP2016518421A (ja) * 2013-05-14 2016-06-23 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール
MX2016001855A (es) * 2013-08-12 2016-05-24 Hoffmann La Roche Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
KR20160030271A (ko) * 2013-08-12 2016-03-16 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 아자-옥소-인돌
HK1222855A1 (zh) 2013-08-15 2017-07-14 F. Hoffmann-La Roche Ag 新的用於治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚
KR20160030569A (ko) * 2013-08-15 2016-03-18 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 신규한 아자-옥소-인돌

Also Published As

Publication number Publication date
AU2015329778A1 (en) 2017-05-04
MX2017004425A (es) 2017-10-11
HRP20190808T1 (hr) 2019-08-23
CA2963740A1 (en) 2016-04-14
JP2017530992A (ja) 2017-10-19
RU2017113026A (ru) 2018-11-13
NZ731323A (en) 2022-09-30
CN107108557B (zh) 2020-11-10
PE20170949A1 (es) 2017-07-13
HUE043553T2 (hu) 2019-09-30
KR20230116097A (ko) 2023-08-03
CN107108557A (zh) 2017-08-29
BR112017007311B1 (pt) 2022-11-22
DK3204375T3 (en) 2019-04-01
ES2718976T3 (es) 2019-07-05
TR201903362T4 (tr) 2019-04-22
MX373233B (es) 2020-05-08
CY1121564T1 (el) 2020-05-29
KR102561796B1 (ko) 2023-07-31
CL2017000839A1 (es) 2017-10-13
PT3204375T (pt) 2019-04-01
SMT201900249T1 (it) 2019-07-11
CO2017004603A2 (es) 2017-10-31
US20170305908A1 (en) 2017-10-26
KR20170066577A (ko) 2017-06-14
LT3204375T (lt) 2019-05-10
WO2016055780A1 (en) 2016-04-14
AU2015329778B2 (en) 2020-04-23
RU2734248C2 (ru) 2020-10-13
RU2017113026A3 (cg-RX-API-DMAC10.html) 2019-03-22
EP3204375B1 (en) 2019-02-13
US10106539B2 (en) 2018-10-23
PL3204375T3 (pl) 2019-06-28
CA2963740C (en) 2022-11-29
EP3204375A1 (en) 2017-08-16
AR102181A1 (es) 2017-02-08
TWI718107B (zh) 2021-02-11
AU2015329778A8 (en) 2017-05-18
RS58706B1 (sr) 2019-06-28
TW201625583A (zh) 2016-07-16
BR112017007311A2 (pt) 2017-12-19
JP6695334B2 (ja) 2020-05-20
SG11201702766YA (en) 2017-05-30
SI3204375T1 (sl) 2019-05-31

Similar Documents

Publication Publication Date Title
IL270954A (en) Pharmaceutical compounds
IL258213A (en) Pharmaceutical compounds
GB201419579D0 (en) Pharmaceutical compound
GB201414730D0 (en) Pharmaceutical compound
GB201504675D0 (en) Pharmaceutical compounds
GB201404922D0 (en) Pharmaceutical compounds
GB201506658D0 (en) Pharmaceutical compounds
GB201519352D0 (en) Pharmaceutical compounds
GB201506660D0 (en) Pharmaceutical compounds
GB201409471D0 (en) Pharmaceutical composition
IL258246A (en) Pharmaceutical compounds
GB201416513D0 (en) Pharmaceutical compounds
GB201409488D0 (en) Pharmaceutical composition
GB201506933D0 (en) Pharmaceutical compounds
GB201502567D0 (en) Pharmaceutical compounds
GB201409485D0 (en) Pharmaceutical composition
EP3189033A4 (en) Pharmaceutical compounds
LT3089740T (lt) Farmacinė kompozicija
SG10201504332VA (en) Pharmaceutical Composition
GB201508022D0 (en) Pharmaceutical compounds
GB201416969D0 (en) Pharmaceutical compounds
GB201416968D0 (en) Pharmaceutical compounds
GB201416627D0 (en) Pharmaceutical compounds
GB201416622D0 (en) Pharmaceutical compounds
GB201416625D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)